Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by HighSkies2019on Oct 19, 2021 3:15pm

100 Views

Post# 34023967

Emergency Use !!!

If Trudeau wanted to make up for the big screw up giving China our IP address to make a CDN vaccine....they should allow health CDA to run a trial of R107 and try make a relationship moving forward...we already read how SanOtize has got emergency use with a NO nasal here and other countries already in use with 99 percent protection.... alot of canadians still on ventalators ....as well many people around the globe... don't understand why they dont take a chance considering its a molecule already produced by our bodies.....W5 put out what happened to our chance to produce our own vaccine and the new blding purchased to produce....go figure...

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments